chevron-down Created with Sketch Beta.
March 18, 2022

Viatris (Mylan) Reaches Deal in EpiPen Pricing Suit

Viatris Inc. agreed to settle litigation over allegations it colluded with Pfizer Inc. over the pricing of EpiPen. A certified class of consumers and third-party payers brought the suit claiming that, as a result of a conspiracy between Mylan (now Viatris) and Pfizer to inhibit the availability of cheaper products, consumers overpaid for the potentially life-saving drug. The judge presiding over the case in the U.S. District Court for the District of Kansas ordered a fairness hearing for July, and, as a result, final approval is pending.